CLPTM1L

Across TCGA pan-cancer cohorts, CLPTM1L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLPTM1L data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CLPTM1L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLPTM1L expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where CLPTM1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.233	1.000	.008	18	view →
HNSC	DFS	Quartile	All	0.808	0.521	.011	12	view →
LSCC	DFS	Tertile	II,III,IV	0.583	0.917	.006	10	view →
GBM	DFS	Tertile	All	0.249	0.420	.042	3	view →
PDAC	DFS	Median	III,IV	0.521	0.225	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLPTM1L–CCRCC (DFS)

Open the CCRCC breakdown →